

October 28, 2025

To

BSE Limited
Corporate Relationship Department
25th Floor, P J Towers
Dalal Street, Fort,
Mumbai – 400 001
BSE Scrip Code: 524743

To

National Stock Exchange of India Ltd. Exchange
Plaza, 5th floor
Plot No. C/ 1, G Block,
Bandra-Kurla Complex Bandra (E),
Mumbai - 400 051
NSE Symbol: FISCHER

Dear Sir/ Madam,

Sub: Disclosure under the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 (read with Para A, Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time ("SEBI Listing Regulations"), we hereby inform you that, based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the appointment of Mr. Chan Sing En (DIN: 11300541), as an Additional Non-Executive Independent Director of the Company, not liable to retire by rotation, for a first term of five consecutive years effective from October 28, 2025, subject to the approval of Shareholders.

It is confirmed that Mr. Chan Sing En is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority and he is not disqualified from holding the office of director pursuant to provisions of Section 164 of the Companies Act, 2013. The disclosure as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed herewith. (Annexure –1)

Further, the Board has recommended the appointment of Tan Sri Dato' Dr. Syed Jalaludin (DIN: 11336135) as the Independent Director of the Company, not liable to retire by rotation, for a first term of five consecutive years effective from the date of approval of Shareholders.

It is confirmed that Dr. Syed Jalaludin is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority and he is not disqualified from holding the office of director pursuant to provisions of Section 164 of the Companies Act, 2013. The disclosure as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed herewith. (Annexure –2)

Please take on record.

Thanking You,
Yours Truly,

For **Fischer Medical Ventures Limited**
(Formerly Known as Fischer Chemic Limited)

Aravindkumar V
Company Secretary and Compliance Officer



ANNEXURE – 1

Details under Regulation 30 of the Listing Regulations read with SEBI Circular No. EBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Name	MR. CHAN SING EN
DIN	11300541
Reason for change viz. appointment, reappointment, resignation, removal, death or otherwise	Appointment of Mr. Chan Sing En (DIN: 11300541), as an Additional Non-Executive Independent Director of the Company
Date of appointment/re-appointment/cessation (as applicable) & term of appointment/reappointment	Appointment of Mr, Chan Sing En (DIN: 11300541), as an Additional Non-Executive Independent Director of the Company, not liable to retire by rotation, for a first term of five consecutive years effective from October 28, 2025, subject to the approval of Shareholders.
Term of appointment/reappointment;	5 years
Brief profile (in case of appointment)	Mr. Chan Sing En is a dynamic investment professional with over three decades of experience spanning Southeast Asia and Australia. He has built a distinguished career in private equity, corporate finance, and operational turnarounds, consistently driving growth and value creation across diverse industries. His deep understanding of financial structuring and market strategy has enabled numerous successful business revitalizations and investor partnerships. As Principal and Director of SovCapital Pte Ltd, Singapore, Mr. Chan leads strategic investment and restructuring initiatives for both private and public companies. He specializes in reverse takeovers, capital raising, and pre-IPO consultancy, offering seasoned guidance to founders and executives. His leadership is marked by a hands-on approach that combines strategic foresight with operational precision. In addition, Mr. Chan serves on the advisory board of FTAG Investment Bank in Malaysia, contributing to high-profile corporate finance transactions and cross-border deals, including the NASDAQ listing of a global supercar brand. A graduate of Pepperdine University, USA, with a degree in Business Administration, he continues to bring financial acumen, boardroom experience, and visionary leadership to every engagement.
Disclosure of relationships between Directors	Mr. Chan Sing En is not related to any other Director of the Company.
Information as required pursuant to BSE Circular ref. no. LIST/COMP/14/2018-19 and NSE ref. no. NSE/ML/2018/24 dated June 20, 2018.	Mr. Chan Sing En is not debarred from holding the office of Director by virtue of any SEBI Order or any such authority

ANNEXURE – 2

Details under Regulation 30 of the Listing Regulations read with SEBI Circular No. EBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Name	TAN SRI DATO' DR. SYED JALALUDIN
DIN	11336135
Reason for change viz. appointment, reappointment, resignation, removal, death or otherwise	Appointment of Dr. Syed Jalaludin En (DIN: 11336135), as an Additional Non-Executive Independent Director of the Company
Date of appointment/re-appointment/cessation (as applicable) & term of appointment/reappointment	Appointment of Dr. Syed Jalaludin (DIN: 11336135), as an Additional Non-Executive Independent Director of the Company, not liable to retire by rotation, for a first term of five consecutive years effective from the date of the approval of Shareholders.
Term of appointment/reappointment;	5 years
Brief profile (in case of appointment)	Tan Sri Dato' Dr. Syed Jalaludin, aged 81 years, is a distinguished academician and visionary leader with over five decades of contribution to Malaysia's higher education, corporate, and public sectors. A PhD graduate from the University of London, he has held numerous pivotal roles including Vice Chancellor of Universiti Putra Malaysia (UPM), Chancellor of Taylor's University, and Chairman of the Board of Directors at Asia e University. His leadership was instrumental in transforming UPM into a premier institution of higher learning and research. Beyond academia, Tan Sri Dato' Dr. Syed Jalaludin has made a significant impact in the corporate sphere, serving as Chairman and Independent Director across major corporations such as PETRON Berhad, Bank Rakyat, and Bioalpha Holdings Berhad. His visionary guidance has driven growth, innovation, and governance excellence in both public and private enterprises, while also advancing Malaysia's position in the global halal industry through his chairmanship at the Halal Industry Development Corporation. He is a Fellow of the Academy of Sciences Malaysia (FASc) and the recipient of numerous national and international honours, including the Panglima Setia Mahkota (P.S.M.) conferred by His Majesty, the Yang di-Pertuan Agong, carrying the title Tan Sri. His lifelong dedication to science, education, and nation-building continues to inspire academic and business communities alike.
Disclosure of relationships between Directors	Dr. Syed Jalaludin is not related to any other Director of the Company.
Information as required pursuant to BSE Circular ref. no. LIST/COMP/14/2018-19 and NSE ref. no. NSE/ML/2018/24 dated June 20, 2018.	Dr. Syed Jalaludin is not debarred from holding the office of Director by virtue of any SEBI Order or any such authority
